Fig. 6: NiV G-specific mAbs proportion and quantification in sera of vaccinated mice. | npj Vaccines

Fig. 6: NiV G-specific mAbs proportion and quantification in sera of vaccinated mice.

From: An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection

Fig. 6

a A competition ELISA showing binding of S1E2 (group 1), S2B10 (group 2), LN3A12 (group 3), LN3D3 (group 4), and HENV-32 (group 5) mAbs to the immobilized NiV sG protein in the presence of 100-fold dilution vaccine-elicited mouse sera (obtained at Day 61, ~three weeks after the third immunization). The binding of these mAbs without vaccine-elicited mouse sera was used as a control, and the OD450 (absorbance at 450 nm) value was defined as 100%. b Quantification of the proportion of different group antibodies in sera from vaccinated mice. ELISA showing binding of NiV sG or NiV G-ferritin vaccinated mouse sera (20000-fold dilution) to the immobilized NiV sG protein in the presence of 10 μg/mL group 1 (S1E2 and LN1D1), group 2 (S2B10), group 3 (LN3A12 and LN3D3), group 4 (LN3E2 and LN3D3) or HENV-32 mAbs. The anti-SFTSV mAb T3D9 was used as a control (not published). Two independent experiments were performed in duplicate, and representative results are shown. Data in each group are presented as mean ± SEM. Statistical significance was determined by the one-way ANOVA with Tukey’s multiple comparisons test. ns not significant, *p < 0.05, **p < 0.01.

Back to article page